This round table was about personal oncology in various subtypes, various areas. The first one is a general overview and then I talked about personalised medicine in lung cancer. I showed several mutations and driver mutations that we have nowadays available by using next generation sequencing exams and after that identified driver mutation which drug you should use. I showed also in my lecture the pitfalls of using only PCR, real time PCR, immunohistochemistry or even FISH to assess these mutations or these drivers. It’s a pitfall because this kind of analysis has to be comprehensive. If you see only a point or a hotspot mutation it can drive a mistake in terms of more rare forms of mutations that are picked up only by using comprehensive exams. So the ideal platform to do this is the next generation sequencing where you have hundreds of mutations and deletions and insertions, you take advantage by finding the correct marker, biological marker, and the driver so that you can choose the right, the correct, treatment.